Presenters, including Nobel Laureate in Medicine, to discuss innovative treatments for neurodegeneration

Company to feature lead therapeutic's statistically significant benefits, p < 0.007, for severe Alzheimer's disease (AD) patients

NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel Alkon, M.D., will join more than 30 leading neuroscientists and academics as a speaker at IABS Forum-2023, "New Concepts for the Treatment of Neurodegenerative Disorders." The distinguished scientific forum, to be held on December 7-8, 2023 in Irvine, CA, is co-sponsored by the University of Southern California School of Pharmacy and the International Association of Biomedical Sciences (IABS).

The forum's keynote address, entitled "Towards a Cell Biology of Alzheimer's Disease," will be delivered by Dr. Thomas Südhof, Nobel Laureate in Physiology or Medicine 2013. Dr. Südhof is known for his groundbreaking research on the mechanisms underlying synaptic transmission, which plays a vital role in learning, memory, and various neurological processes.

AD is also the topic of Dr. Alkon's presentation. He will speak about the latest clinical results for Bryostatin-1, which, as previously disclosed, met the secondary efficacy endpoints in the Phase 2 trial with statistical significance. In the Phase 2 trial, no significant cognitive decline was observed throughout the 10-month study, with Bryostatin-1 demonstrating safe, significant, and persistent benefits at least 16 weeks beyond the final dosing. A research article detailing the results was published earlier this year in the Journal of Alzheimer's Disease.

"I am honored to accept the invitation to speak at IABS Forum-2023, in the company of many of the world's greatest minds in neuroscience," said Dr. Alkon. "Renowned institutions, publishers, and symposiums continue to recognize the benefits of our novel therapy, developed to restore synaptic loss, and its potential for advanced stage Alzheimer's patients."

About Synaptogenix

Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.